International HIT-MED Registry

Medulloblastom, Ependimom, Pineoblastom, CNS-PNET

Register

• To evaluate clinical data on the epidemiology of the above mentioned CNS-neoplasms, and the use and outcome of different treatment regimens, for patients who cannot be included in prospective trials.
• To provide guidelines to establish, maintain and improve systems for quality assurance in the diagnostic assessments and treatment of brain tumours.
• To collect biological specimens (tumour, CSF, peripheral blood) and perform comprehensive biological studies with the aim to improve our understanding of these diseases and their aetiology, to improve therapy stratification and to improve or develop new treatment options.
• To collect clinical data for cooperative scientific projects (e.g. new follow-up studies, studies on quality of survival, neuropsychology etc.)

• Children and adults with histologically proven: Medulloblastoma (MB); Ependymoma; CNS-primitive neuroectodermal tumours -CNS-PNET- ( including CNS neuroblastoma, CNS ganglioneuroblastoma, Medulloepithelioma, Ependymoblastoma); Pineoblastoma; Pineal parenchymal tumour of intermediate differentiation; Papillary tumour of the pineal region
• All ages (except for ependymoma WHO I°, pineal parenchymal tumour of intermediate differentiation and papillary tumour of the pineal region, who will be registered only if primary diagnosis was before the 18th birthday)
• Any localisation of the primary tumour
• All clinical stages

• Registration in another clinical trial for the same diagnosis (relapse is defined as a second diagnosis).
• Lack of valid ethical committee approval.